AIM ImmunoTech CEO and President Equels Thomas K purchased 22,000 shares at $0.22 each on September 15, 2026, in an open-market transaction classified with code P. His resulting holding was 91,822 shares, while the purchase represented about 24.0% of that holding, giving investors a stated view of the transaction’s size.
Key Highlights
- Equels Thomas K’s resulting AIM ImmunoTech holding stood at 91,822 shares.
- Transaction code P identifies the purchase as an open-market transaction.
- The transaction represented about 24.0% of Equels Thomas K’s resulting share holding.
AIM ImmunoTech Inc. (AMEX: AIM) CEO & President Equels Thomas K bought 22,000 shares at $0.22 per share. The purchase took place on 15 September 2026, placing the total transaction value on a per-share basis at the reported price.
Open-Market Purchase Recorded Transaction
code P classifies the deal as an open-market purchase. Following the transaction, Equels Thomas K owned 91,822 AIM ImmunoTech shares. The reported purchase represented about 24.0% of his resulting share holding.
FAQs
Q: How many AIM ImmunoTech shares did Equels Thomas K buy?
A: Equels Thomas K bought 22,000 AIM ImmunoTech shares at $0.22 per share on 15 September 2026. The transaction used code P.
Q: What was Equels Thomas K’s AIM ImmunoTech share holding after the purchase?
A: His reported AIM ImmunoTech holding after the transaction was 91,822 shares. The purchase represented about 24.0% of that resulting holding.
Q: What does transaction code P mean for the AIM ImmunoTech purchase?
A: Code P denotes an open-market purchase in transaction reporting. The recorded buyer was Equels Thomas K, identified as CEO & President.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.